Skinhealth Systems

SKIN · NASDAQ

$11.16+$0.61 (+5.78%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.55

SKIN analyst rating

HoldConsensus of 4 analysts over the last 12 months. 25% rate it a buy.

Strong buy0
Buy1
Hold3
Underperform0
Sell0

12-month price target · 8 analysts

Average $1.01 (−90.9% downside)

Low: $0.707
Now: $11.16
High: $1.58

Upgrades and downgrades

The latest rating actions, newest first

SKIN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Jefferies	Oct 19, 2026	Maintains	Hold	$0.85 → $11.00	38%
TD Cowen	Aug 12, 2026	Maintains	Hold	$1.00 → $0.90	51%
Roth Capital	May 20, 2026	Maintains	Buy	$2.50 → $2.00	49%
Canaccord Genuity	May 1, 2026	Maintains	Hold	$1.50 → $1.00	42%
TD Cowen	Mar 16, 2026	Maintains	Hold	$1.65 → $1.50	51%
Canaccord Genuity	Mar 13, 2026	Maintains	Hold	$1.50	42%
TD Cowen	Jan 21, 2026	Maintains	Hold	$1.50 → $1.65	51%
Jefferies	Jan 14, 2026	Initiates	Hold	$1.60	38%

The case for and against

Updated Oct 16, 2026

Bull case

SkinHealth Systems is attractive fundamentally because its installed base of 36,516 systems and roughly 75% consumables-driven revenue create a recurring, high-margin model that can compound as utilization improves. Despite 2Q26 revenue falling 8% to $72.1M, adjusted EBITDA rose to $17.0M, helped by gross margin expansion to 71.8% and disciplined expense control, while the new U.S. rental program should ease provider financing constraints and support placements. The outlook is further strengthened by adjacent-category momentum, including SkinStylus growing nearly 50% y/y and HydraScalp’s relaunch traction, alongside upcoming clinical and platform launches that broaden future growth drivers.

Bear case

SkinHealth Systems is facing a deteriorating fundamental setup because its $91M market cap sits well below its ~$206M cash balance, yet investors still must underwrite weak conversion of profitability into durable free cash flow and a $250MM November 2028 convertible maturity that remains a balance-sheet overhang. Revenue visibility is poor after FY26 guidance was reduced, 3Q26 revenue of $65-70MM and adj. EBITDA of $5-7MM imply continued declines, and 2Q showed Delivery Systems revenue down 18% y/y while Consumables fell 4% y/y amid pressured utilization and tougher competition. Installed-base productivity also looks weak, with 770 placements generating only 97 net additions, while litigation, regulatory risk, and one-time restructuring costs threaten to keep cash flow and brand momentum under pressure.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.